Boni Elewski
Dermatology · Birmingham, ALNPI 1437192317
Payments from drug & device makers
Across 867 payments — averaging $6331.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$736K
- Eli Lilly$730K
- UCB SA$720K
- Pfizer$667K
- AbbVie$528K
- Novartis$497K
- plus $1.6M from 25 others
Across 14 payments — averaging $13,069 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma Inc.$172K
- Eli Lilly$8K
- Novartis$3K
What the payments were for
- Consulting fees$200,72874%
- Speaking & faculty fees$43,61916%
- Travel & lodging$20,3107%
- Food & beverage$5,6042%
- Education$6670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 39 | $736,139 |
| Eli Lilly | 44 | $730,206 |
| UCB SA | 15 | $719,547 |
| Pfizer | 167 | $667,427 |
| AbbVie | 115 | $527,932 |
| Novartis | 36 | $496,586 |
| E.r. Squibb & Sons, L.L.C. | 21 | $354,811 |
| LEO Pharma AS | 24 | $353,380 |
| Incyte Corporation | 115 | $235,139 |
| Janssen Research & Development, LLC | 32 | $193,350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $98,823 |
| Boehringer Ingelheim | 23 | $80,235 |
| Boehringer Ingelheim International GmbH | 50 | $58,806 |
| Galderma Laboratories, L.p. | 34 | $34,154 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 40 | $32,213 |
| Bristol Myers Squibb | 15 | $25,307 |
| VYNE Pharmaceuticals Inc. | 9 | $23,662 |
| Lilly USA, LLC | 4 | $20,149 |
| UCB, Inc. | 20 | $18,658 |
| Johnson & Johnson | 27 | $17,558 |
| LEO Pharma Inc. | 8 | $16,495 |
| Vanda Pharmaceuticals Inc. | 4 | $16,211 |
| Bausch Health US, LLC | 5 | $15,796 |
| Merck | 3 | $5,219 |
| Sun Pharmaceutical Industries Inc. | 2 | $3,634 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $3,158 |
| Janssen Global Services, LLC | 3 | $2,411 |
| EMD Serono, Inc. | 1 | $1,625 |
| Almirall LLC | 1 | $850 |
| Janssen Scientific Affairs, LLC | 2 | $65 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,489,560 in reported general payments places this provider in the 95th percentile of 168 dermatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 90 | $321,614 |
| TremfyaGuselkumab | 16 | $206,848 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $206,534 |
| Humira(Cf) PenAdalimumab | 16 | $179,658 |
| OtezlaApremilast | 28 | $115,795 |
| RinvoqUpadacitinib | 17 | $102,692 |
| Fluocinonide | 19 | $1,077 |
| Azelaic Acid | 15 | $1,075 |
| Clindamycin Phosphate | 25 | $989 |
| Dutasteride | 30 | $932 |
| Ketoconazole | 48 | $898 |
| Doxycycline Hyclate | 25 | $817 |
| Doxycycline Monohydrate | 32 | $737 |
| Hydroxychloroquine Sulfate | 28 | $661 |
| Triamcinolone Acetonide | 33 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $17,558 | $206,84816 claims |
| AmgenOtezla | $736,139 | $115,79528 claims |
| AbbVieRinvoq | $527,932 | $102,69217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 168 dermatology providers in Alabama.
Other dermatology in Birmingham
- James KrellBirmingham$4M
- Tiffany MayoBirmingham$1.4M
- Melanie AppellBirmingham$983K
- Julie HarperBirmingham$920K
- Corey HartmanBirmingham$744K
- Lauren GrahamBirmingham$582K
- Kristy CurlBirmingham$158K
- Rajini MurthyBirmingham$153K
- Sarah Lauren HugheyBirmingham$144K
- Megan CherryBirmingham$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.